Research

Hormonal

Acarbose treatment improves metabolic parameters (BMI, insulin resistance, lipid profile) in type 2 diabetes patients by altering gut microbiota to increase the ratio of primary to secondary bile acids, but this benefit is contingent on the patient's baseline microbiota composition.

If you are starting treatment for Type 2 Diabetes, ask your doctor about the potential role of your gut health. This research suggests that a specific type of diabetes medication (Acarbose) works better for people who have a certain gut bacteria profile (high Bacteroides). It alters bile acids to improve metabolism, not just blood sugar. This is not a general recommendation for all patients, but a stratification strategy.

GoodConditionalHIGH confidence
Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment.
Yanyun Gu et al. · Nature Communications · 2017

Why this rating

Randomized controlled trial with stratification, but sample size is moderate (n=94 analyzed) and specific to a Chinese population.

Source

Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

Yanyun Gu et al. · Nature Communications · 2017

DOI 10.1038/s41467-017-01682-2

rct · n=94Cited 409×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →